BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 28885219)

  • 21. Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study.
    López-Centeno B; Badenes-Olmedo C; Mataix-Sanjuan Á; McAllister K; Bellón JM; Gibbons S; Balsalobre P; Pérez-Latorre L; Benedí J; Marzolini C; Aranguren-Oyarzábal A; Khoo S; Calvo-Alcántara MJ; Berenguer J
    Clin Infect Dis; 2020 Jul; 71(2):353-362. PubMed ID: 31428770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.
    Okoli C; Schwenk A; Radford M; Myland M; Taylor S; Darley A; Barnes J; Fox A; Grimson F; Reeves I; Munshi S; Croucher A; Boxall N; Benn P; Paice A; van Wyk J; Khoo S
    HIV Med; 2020 Sep; 21(8):471-480. PubMed ID: 32671950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda.
    Eneh PC; Hullsiek KH; Kiiza D; Rhein J; Meya DB; Boulware DR; Nicol MR
    BMC Infect Dis; 2020 Aug; 20(1):572. PubMed ID: 32758158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study.
    Schlaeppi C; Vanobberghen F; Sikalengo G; Glass TR; Ndege RC; Foe G; Kuemmerle A; Paris DH; Battegay M; Marzolini C; Weisser M;
    HIV Med; 2020 Jan; 21(1):53-63. PubMed ID: 31532898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of antiretroviral multidrug resistance in highly active antiretroviral therapy-treated patients with HIV/AIDS between 2004 and 2009 in South Korea.
    Choi JY; Kwon OK; Choi BS; Kee MK; Park M; Kim SS
    J Clin Virol; 2014 Jun; 60(2):154-60. PubMed ID: 24680255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors.
    Yeşilbağ Z; Şengül Eİ; Şenoğlu S; Aydın ÖA; Karaosmanoğlu HK
    Curr HIV Res; 2020; 18(6):415-425. PubMed ID: 32787762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.
    Chastain DB; Franco-Paredes C; Stover KR
    J Clin Pharmacol; 2017 Nov; 57(11):1387-1399. PubMed ID: 28884831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
    van Lunzen J; Liess H; Arastéh K; Walli R; Daut B; Schürmann D
    HIV Med; 2007 May; 8(4):220-5. PubMed ID: 17461849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy.
    Sangiovanni RJ; Jakeman B; Nasiri M; Ruth L; Mahatme S; Patel N
    AIDS Res Hum Retroviruses; 2019 May; 35(5):430-433. PubMed ID: 30612438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS?
    Ceballos-Salobreña A; Gaitán-Cepeda LA; Ceballos-Garcia L; Lezama-Del Valle D
    AIDS Patient Care STDS; 2000 Dec; 14(12):627-35. PubMed ID: 11119429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa.
    Katende-Kyenda NL; Lubbe MS; Serfontein JH; Truter I
    S Afr Med J; 2008 Feb; 98(2):109-13. PubMed ID: 18350204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
    Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
    Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
    Loulergue P; Merad M; Coriat R; Ducreux M; Planchard D; Boige V; Le Cesne A; Gregory TM; Poinsignon V; Paci A; Mir O
    Invest New Drugs; 2017 Apr; 35(2):247-249. PubMed ID: 27838867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.
    Pollack TM; McCoy C; Stead W
    Pharmacotherapy; 2009 Nov; 29(11):1386-91. PubMed ID: 19857154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.